Rare blood cancer (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Who can joinChildren and adults

AgeAsk the trial team

Kind of studyObservational: no new treatment

What it testsWatches and records only

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

1 hospital in India taking patients for this trial.

Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical SciencesNew DelhiDirections ↗

Registry summary (technical)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different tre…

Sponsor: Immune Oncology Research Institute
NCT05430971 on ClinicalTrials.gov
Last updated on the registry 5 Jun 2026 · read by us 20 Oct 2026

Rare blood cancer (BPDCN)

Where to go

Need help reaching the trial team? Write to us.